

K 113792 : 1/2

JAN 19 2012

510(k) Summary
MegaBeam Endocular Probe and Aspirating Endocular Probe

**Submitter's Name, Address, Telephone Number, Contact Person
and Date Prepared**

Biolitec Medical Devices, Inc.
515 Shaker Road
East Longmeadow, Massachusetts 01028
Phone: (413) 525-0600
Facsimile: (413) 525-0611

Contact Person: Harry Hayes, Ph.D. – Regulatory Consultant
Date prepared: December 20, 2011

Name of Device and Name/Address of Sponsor

MegaBeam Endocular Probe and Aspirating Endocular Probe Biolitec Medical
Devices, Inc.
515 Shaker Road
East Longmeadow, Massachusetts 01028

Classification Name

Surgical laser accessory

Predicate Devices

MegaBeam Endocular Probe, (K935747).
MegaBeam Aspirating Endocular Probe, (K952340).

Intended Use/Indication for Use

The MegaBeam Endocular Probe and Aspirating Endocular Probe are intended for intraocular photocoagulation with or without simultaneous aspiration/ irrigation as an adjunct to vitrectomy surgery. Specific indications include the treatment of proliferative vitreoretinopathy, tractional retinal detachments, proliferative diabetic retinopathy, and various retinal vascular tumors.

Technological Characteristics

The MegaBeam Endocular Probe and Aspirating Endocular Probe for Biolitec Medical Devices, Inc. contains the same components and design as the devices cleared under K935747 and K952340 for Biolitec Inc. except for a small change in tip size, (19 gauge to 25 gauge). There are no differences in technology and as such does not raise any new questions on safety or efficacy.

K113792 2/2

Performance Data

Since the performance of the MegaBeam Endocular Probe and Aspirating Endocular Probe is well established and documented no performance testing is being specifically included in this submission.

Substantial Equivalence

The MegaBeam Endocular Probe and Aspirating Endocular Probe are as safe and effective for these Indications for Use as the MegaBeam Endocular Probe and Aspirating Endocular Probe predicate devices. Thus, the MegaBeam Endocular Probe and Aspirating Endocular Probe for Biolitec Medical Devices, Inc. is substantially equivalent to its predicate device.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

Biolitec Medical Devices, Incorporated
% Harry Hayes, Ph.D.
Regulatory Consultant
515 Shaker Road
East Longmeadow, Massachusetts 01028

JAN 19 2012

Re: K113792

Trade/Device Name: MegaBeam Endocular Probe and Aspirating Endocular Probe

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery
and in dermatology

Regulatory Class: Class II

Product Code: GEX, HQF

Dated: December 22, 2011

Received: December 23, 2011

Dear Dr. Hayes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set


Page 2 – Harry Hayes, Ph.D.

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson" with a stylized flourish at the end.

Mark N: Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): K 113792

Device Name: **MegaBeam Endocular Probe and Aspirating Endocular Probe.**

Indications for Use: The MegaBeam Endocular Probe and Aspirating Endocular Probe are intended for intraocular photocoagulation with or without simultaneous aspiration/ irrigation as an adjunct to vitrectomy surgery. Specific indications include the treatment of proliferative vitreoretinopathy, tractional retinal detachments, proliferative diabetic retinopathy, and various retinal vascular tumors.

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nick A. Ogden *for man*
(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

510(k) Number K 113792

Prescription Use ✓
(Per 21 C.F.R. 801.109)

OR

Over-The-Counter Use
(Optional Format 1-2-96)